Clinical trial
Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation…
NCT00389532 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00389532 |
|---|---|
| Title | Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine |
| Official title | Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Influenza Virus Vaccine (2006-2007 Fluzone® vaccine) |
| Enrollment | 116 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Oct 19, 2006 |
| Last update posted | Apr 14, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: